IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
17 Octobre 2017 - 6:37AM
Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that
new data investigating the use of eftilagimod alpha (IMP321), the
Company’s lead product candidate, in combination with pembrolizumab
in metastatic melanoma patients in Australia that have had either
no response or a suboptimal response to pembrolizumab, will be
presented in a poster presentation for the first time at the
Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting.
Pushing the accelerator and releasing the break: testing
the soluble LAG-3 protein (IMP321), an antigen presenting cell
activator, together with pembrolizumab in unresectable or
metastatic melanoma. Poster Number P259
Authors: Victoria Atkinson, Andrew Haydon, Melissa
Eastgate, Amitesh Roy, Adnan Khattak, Christian Mueller, Tina
Dunkelmann, Chrystelle Brignone, Frederic Triebel The SITC 2017
Annual Meeting is being held on November 10-12, 2017 at the Gaylord
National Hotel & Convention Center in National Harbor,
Maryland.
Prima BioMed
Prima BioMed is listed on the Australian
Securities Exchange and on the NASDAQ in the US. For further
information please visit www.primabiomed.com.au.
For further information please
contact:
U.S. Investors:Matthew Beck, The Trout Group
LLC+1 (646) 378-2933; mbeck@troutgroup.com
Australian
Investors/Media:Matthew Gregorowski, Citadel-MAGNUS+61 2
8234 0105; mgregorowski@citadelmagnus.com
Immutep Limited (NASDAQ:PBMD)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Immutep Limited (NASDAQ:PBMD)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Immutep Limited (NASDAQ): 0 recent articles
Plus d'articles sur